Zirconium Zr 89 Girentuximab

Phase 2Monoclonal antibody

JJonsson Comprehensive Cancer Center

Zirconium Zr 89 Girentuximab is one of 29 small molecule programs targeting Kidney Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerRecruiting

Kidney CancerPhase 2

Recruiting

Competition

Competitive Landscape

31 competitors in Kidney Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

17 2

Yervoy

Bristol-Myers Squibb

Approved

9 3

Avastin

Roche

Phase 3

21 4

Tabrecta

Precose

Votrient

11 7

Keytruda

Merck & Co.

Phase 3

8 8

Cabometyx

Bristol-Myers Squibb

Phase 3

7 9

Afinitor

Novartis

Phase 3

6 10

Osmitrol

BB. Braun Medical Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Recruiting

Kidney Cancer

NCT06447103

Clinical

Trials by Indication[1]

Kidney Cancer1 trial

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06447103·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zirconium Zr 89 Girentuximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zirconium Zr 89 Girentuximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zirconium Zr 89 Girentuximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

Zirconium Zr 89 Girentuximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News